Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary

• DOI: 10.1038/s41416-022-01824-4
• Publication Date: 2022-04-28T17:30:54Z
• Authors: Alicia-Marie Conway; Georgina C. Morris; Sarah Smith; Monique Vekeria; Prakash Manoharan; Claire Mitchell; Alison Backen; Pedro Oliveira; Richard A. Hubner; Angela Lamarca; Mairéad G. McNamara; Juan W. Valle; Natalie Cook
• Keywords: Male; 0301 basic medicine; Middle Aged; ResearchInstitutes_Networks_Beacons/mcrc; name=Manchester Cancer Research Centre; Article; 3. Good health; Cholangiocarcinoma; 03 medical and health sciences; Bile Ducts, Intrahepatic; Bile Duct Neoplasms; Humans; Neoplasms, Unknown Primary; Female; Retrospective Studies

Abstract Background Many patients referred with a provisional diagnosis of cancer of unknown primary (pCUP) present with presumed metastatic disease to the liver. Due to the lack of definitive histological markers, intrahepatic cholangiocarcinoma (iCCA) may be overlooked. This study assessed the frequency of iCCA within a pCUP cohort.

Methods A single UK cancer-center study of sequential patients referred with pCUP from January 2017 to April 2020. Baseline diagnostic imaging was reviewed independently by a radiologist and oncologist; those with radiological features of iCCA (dominant liver lesion, capsular retraction) were identified.

Results Of 228 patients referred with pCUP, 72 (32%) had malignancy involving the liver. 24/72 patients had radiological features consistent with iCCA; they were predominantly female (75%) with an average age of 63 years and 63% had an ECOG PS ≤ 2. The median overall survival (OS) of the iCCA group and the remaining liver-involved CUP group were similar (OS 4.1 vs 4.4 months, p-value = 0.805). Patients, where a primary diagnosis was subsequently determined, had better OS (10.2 months, p-values: iCCA = 0.0279: cCUP = 0.0230).

Conclusions In this study, 34% of patients with liver-involved pCUP, fulfilled the radiological criteria for an iCCA diagnosis. Consideration of an iCCA diagnosis in patients with CUP could improve timely diagnosis, molecular characterisation and treatment.